Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexstim PLC

www.nexstim.com

Latest From Nexstim PLC

Australia Clears Nexstim Neuromodulation Depression Treatment

Neuromodulation firm Nexstim has received regulatory clearance for its SmartFocus TMS system for treating major depressive disorder (MDD) in Australia.

Australia Approvals

Nexstim Targets Canadian Market With New Distributor Agreement

Neuromodulation firm Nexstim will launch its SmartFocus TMS system for treating major depressive disorder (MDD) in Canada after signing an exclusive agreement with distributor Canada Health Solutions CHS.

Canada Deals

Nexstim Looks To Break Into US TMS Market With Depression Indication

The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.

Clinical Trials Innovation

Neuronetics Launches Major Registry To Track NeuroStar TMS Outcomes

The registry will collect data from more than 6,000 depression patients treated with transcranial magnetic stimulation at more than 100 different treatment facilities in the US to better understand how the therapy benefits patients in the "real world."

Research & Development Innovation
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • MRI, NMR
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Nexstim Ltd.
  • Nexstim Oy
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Finland
  • Parent & Subsidiaries
  • Nexstim PLC
  • Senior Management
  • Janne Huhtala, CEO
    Mikko Karvinen, CFO
    Gustaf Jarnefelt, VP, R&D
    Henri Hannula, VP, Sales Europe
  • Contact Info
  • Nexstim PLC
    Phone: (358) 9 2727 1710
    Elimäenkatu 9 B
    Helsinki, FI-00510
    Finland
Advertisement
Advertisement
UsernamePublicRestriction

Register